Bladder Cancer - Results from #100

REVIEW UroToday

Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer. September 16, 2024

Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study. September 16, 2024

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma September 15, 2024

Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer. September 13, 2024

Perioperative platform for muscle-invasive bladder cancer trials: designs and endpoints. September 13, 2024

The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer. September 12, 2024

Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer. September 12, 2024

Urinary mRNA-based biomarkers for non-muscle-invasive bladder cancer: a mini-review. September 12, 2024

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer. September 11, 2024

Stent vs Stent-Less Ileal Conduits After Radical Cystectomy: Is There a Difference in Early Postoperative Outcomes? September 11, 2024

Patient-derived Organoids in Bladder Cancer: Opportunities and Challenges. September 11, 2024

The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma - A review of the literature. September 11, 2024

Variation in cystectomy pathology reporting practice-results from an international survey of 212 pathologists. September 10, 2024

Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. September 10, 2024

Modeling Historic Arsenic Exposures and Spatial Risk for Bladder Cancer. September 10, 2024

E-learning pills on immunotherapy in urothelial carcinoma: The E-PIMUC program for continuing medical education. September 9, 2024

A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer. September 9, 2024

Pre-Op Hydronephrosis Predicts Outcomes in Patients Receiving Robot-Assisted Radical Cystectomy. September 9, 2024

Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding. September 9, 2024

Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis. September 6, 2024

Page 6 of 517